ProfileJobs

Epizyme

Healthbiotechoncologypharma

Epizyme is a clinical stage biopharmaceutical company creating epigenetic therapeutics for patients with cancer. The Company is focused on creating medicines that are targeted at specific causes of diseases, that are orally administered, tolerable, easy to take, and that are based on a deep understanding of the patients that will benefit from them. 

Based on clinical proof of concept in treating multiple forms of cancer, Epizyme's lead product candidate, tazemetostat, is being developed for hematologic malignancies and genetically defined solid tumors. The Company is also advancing novel compounds directed against a broad range of disease targets.

Revenue(FY, 2016)
$8 M
Market capitalization(2017-08-18)
$820.2 M
Company Growth (employees)
Type
Public
HQ
Cambridge, US
Founded
2007
Size (employees)
112 (est)+26%
Website
epizyme.com
Epizyme was founded in 2007 and is headquartered in Cambridge, US

Key People at Epizyme

Robert A. Copeland

Robert A. Copeland

Executive Vice President and Chief Scientific Officer

Epizyme Office Locations

Epizyme has an office in Cambridge
Cambridge, US (HQ)
400 Technology Square

Epizyme Data and Metrics

Epizyme Financial Metrics

Epizyme's revenue was reported to be $8 m in FY, 2016
USD

Net income (Q1, 2017)

(32.5 m)

EBIT (Q1, 2017)

(33 m)

Market capitalization (18-Aug-2017)

820.2 m

Cash (31-Mar-2017)

64.4 m
Epizyme's current market capitalization is $820.2 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

68.5 m41.4 m2.6 m8 m

Revenue growth, %

(40%)(94%)213%

R&D expense

91.5 m

General and administrative expense

28.4 m

Operating expense total

71.6 m96.5 m135.1 m119.8 m

EBIT

(3.1 m)(55.1 m)(132.5 m)(111.8 m)

EBIT margin, %

(5%)(133%)(5178%)(1397%)

Interest income

74 k95 k

Pre tax profit

(3.1 m)(54.9 m)(132.4 m)(110.2 m)

Income tax expense

349 k109 k

Net Income

(3.5 m)(55 m)(132.4 m)(110.2 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

R&D expense

17.5 m22.2 m57.1 m20.6 m16.8 m17.7 m21.5 m23.9 m24.7 m

General and administrative expense

5.3 m5.7 m5.2 m6 m6.7 m5.8 m7.4 m7.5 m8.3 m

Operating expense total

22.8 m27.9 m62.3 m26.5 m23.5 m23.6 m28.9 m31.4 m33 m

EBIT

(13.3 m)(19.7 m)(61.4 m)(25.8 m)(23.1 m)(23.1 m)(28.4 m)(24.8 m)(33 m)

Interest income

26 k24 k31 k

Pre tax profit

(13.3 m)(19.7 m)(25.8 m)(23.1 m)

Income tax expense

113 k5 k113 k5 k

Net Income

(20.3 m)(40 m)(61.3 m)(25.8 m)(23.1 m)(22.9 m)(28 m)(24.3 m)(32.5 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

123.6 m190.1 m208.3 m77.9 m

Accounts Receivable

33.7 m2.1 m262 k23 k

Inventories

2.4 m2.8 m4.5 m6.5 m

Current Assets

159.7 m195 m213.1 m248.7 m

PP&E

2.2 m3.6 m4.1 m3.1 m

Total Assets

163 m199.2 m217.9 m252.4 m

Accounts Payable

4.7 m8.3 m4.7 m5 m

Current Liabilities

34.6 m17 m18.4 m21.6 m

Additional Paid-in Capital

160.4 m271.4 m413 m555.5 m

Retained Earnings

(56.1 m)(111.1 m)(243.5 m)(353.7 m)

Total Equity

104.3 m160.3 m169.5 m201.7 m

Financial Leverage

1.6 x1.2 x1.3 x1.3 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

229.9 m211.7 m244.5 m236.7 m229.9 m312.7 m89.5 m66 m64.4 m

Accounts Receivable

2.2 m2.1 m365 k723 k177 k176 k60 k6.2 m8 k

Current Assets

234.7 m217.1 m247.4 m239.4 m232.6 m318.3 m296.6 m275 m220 m

PP&E

2.6 m2.7 m5.2 m4.9 m4.5 m3.8 m3.6 m3.3 m3.3 m

Total Assets

238.4 m220.8 m253.3 m245 m237.7 m322.7 m300.9 m279 m223.9 m

Accounts Payable

4.5 m5.7 m5.1 m3 m3 m2.2 m3.7 m3.4 m7.3 m

Current Liabilities

23.8 m23.8 m11.9 m13.2 m17.5 m14 m16.2 m15.9 m20.5 m

Additional Paid-in Capital

266 m268.8 m390.8 m407.1 m410.8 m545.3 m549.5 m552.5 m560.9 m

Retained Earnings

(76.4 m)(96.1 m)(172.4 m)(198.2 m)(221.2 m)(266.3 m)(294.3 m)(318.7 m)(386.3 m)

Total Equity

189.6 m172.8 m218.4 m208.9 m189.6 m279 m255.2 m233.8 m174.5 m

Financial Leverage

1.3 x1.3 x1.2 x1.2 x1.3 x1.2 x1.2 x1.2 x1.3 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(3.5 m)(55 m)(132.4 m)(110.2 m)

Depreciation and Amortization

703 k742 k1.4 m1.6 m

Accounts Receivable

(32 m)31.6 m1.8 m239 k

Inventories

(1.5 m)(419 k)(1.6 m)(1.5 m)

Accounts Payable

1.6 m3.6 m(3.6 m)341 k

Cash From Operating Activities

(53.7 m)(35.4 m)(72.9 m)(96.4 m)

Purchases of PP&E

(630 k)(2.2 m)(183 k)(624 k)

Cash From Investing Activities

(630 k)(2.2 m)(40.2 m)(165.4 m)

Cash From Financing Activities

79.9 m104.1 m131.3 m131.4 m

Income Taxes Paid

963 k963 k963 k
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(20.3 m)(40 m)(61.3 m)(25.8 m)(23.1 m)(22.9 m)(28 m)(24.3 m)(32.5 m)

Depreciation and Amortization

362 k548 k260 k389 k

Accounts Receivable

31.5 m31.6 m1.7 m723 k177 k86 k60 k6.2 m8 k

Accounts Payable

(142 k)1.1 m(3.2 m)3 m3 m(2.4 m)3.7 m3.4 m7.3 m

Cash From Operating Activities

4.7 m(14.4 m)(22.7 m)(25.4 m)

Purchases of PP&E

(824 k)(1.2 m)(163 k)(70 k)

Cash From Investing Activities

(824 k)(1.2 m)(40.2 m)(70 k)

Cash From Financing Activities

102.5 m103.7 m117.3 m129.8 m

Income Taxes Paid

2 k
Y, 2017

Financial Leverage

1.3 x

Epizyme Market Value History

Market Position of Epizyme

Competitors

PDL BioPharma
Health - Public
GTx
Health - Public
Rexahn Pharmaceuticals
Health - Public
Bellicum Pharmaceuticals
Health - Public
Compare competitors

Traffic Overview of Epizyme

Epizyme Online and Social Media Presence

Epizyme Company Life and Culture

You may also be interested in